Soluble CD163 in young sickle cell disease patients and their trait siblings: A biomarker for pulmonary hypertension and vaso-occlusive complications

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 7, 2012, Pages 640-648

  Tantawy, Azza Abdel Gawad ^a   Adly, Amira Abdel Moneam ^a   Ismail, Eman Abdel Rahman ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Hydroxyurea; Pulmonary hypertension; sCD163; Sickle cell disease; Trait; Vaso occlusive crisis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD163 ANTIGEN; HEMOGLOBIN; HYDROXYUREA;

ACUTE CHEST SYNDROME; ADOLESCENT; ARTICLE; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; CHILD; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; GENETIC TRAIT; HUMAN; LEUKOCYTE COUNT; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SIBLING; SICKLE CELL ANEMIA; SICKLE CELL CRISIS;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; CHILD; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; RECEPTORS, CELL SURFACE; SIBLINGS;

EID: 84867006894     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283573a42     Document Type: Article

References (45)

1. Rees DC, Williams TN, Gladwin MT. Sickle cell disease. Lancet 2010; 376:2018-2031.
2. Smiley D, Dagogo-Jack S, Umpierrez G. Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab 2008; 4:102-109. (Pubitemid 351156887)
3. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2005; 19:881-896. (Pubitemid 41427115)
4. Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica 2007; 92:1549-1552. (Pubitemid 350144130)
5. Machado RF. Pulmonary hypertension in sickle cell disease. PVRI Rev 2009; 1:6-12.
6. Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med 2004; 350:857-859. (Pubitemid 38252531)
7. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004; 364:1343-1360. (Pubitemid 39335827)
8. John N. A review of clinical profile in sickle cell traits. Oman Med J 2010; 25:3-8.
9. Eichner ER. Sickle cell trait. J Sport Rehabil 2007; 16:197-203.
10. Van Gorp H, Van Breedam W, Van Doorsselaere J, Delputte PL, Nauwynck HJ. Identification of the CD163 protein domains involved in infection of the porcine reproductive and respiratory syndrome virus. J Virol 2010; 84:3101-3105.
11. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409:198-201. (Pubitemid 32144285)
12. Fabriek BO, Polfliet MM, Vloet RP, van der Schors RC, Ligtenberg AJ, Weaver LK, et al. The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. Blood 2007; 109:5223-5229. (Pubitemid 46890540)
13. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007; 178:8183-8194. (Pubitemid 46898091)
14. Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, et al. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 2009; 113:887-892.
15. Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, NakamuraM, Matsuda T, et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 2002; 130:156-161.
16. Møller HJ, Nielsen MJ, Maniecki MB, Madsen M, Moestrup SK. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. Immunobiology 2010; 215:406-412.
17. Møller HJ, Aerts H, Grønbaek H, Peterslund NA, Hyltoft Petersen P, Hornung N, et al. Soluble CD163: a marker molecule for monocyte/ macrophage activity in disease. Scand J Clin Lab Invest Suppl 2002; 237:29-33.
18. Onofre G, Kolácková M, Jankovicová K, Krejsek J. Scavenger receptor CD163 and its biological functions. Acta Medica (Hradec Kralove) 2009; 52:57-61.
19. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383-1389. (Pubitemid 36019423)
20. Belcher JD, Bryant CJ, Nguyen J, Bowlin PR, Kielbik MC, Bischof JC, et al. Transgenic sickle mice have vascular inflammation. Blood 2003; 101:3953-3959. (Pubitemid 36857872)
21. Moller HJ, Nielsen MJ, Bartram J, Dick MC, Height SE, Moestrup SK, et al. Soluble CD163 levels in children with sickle cell disease. Br J Haematol 2011; 153:105-110.
22. Tonbary YA, Elashry R, Zaki Mel S. Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, egypt: retrospective analysis. Mediterr J Hematol Infect Dis 2010; 2:e2010025.
23. Wethers WY. Sickle cell disease in childhood: Part I. Laboratory diagnosis, pathophysiology and health maintenance. Am Fam Physician 2000; 62:1013-1020.
24. Lal A, Vichinsky EP. Sickle cell disease. In: Hoffbrand AV, Catovsky D, Tuddenham EGD, eds. Postgraduate haematology. 5th edn. Massachusetts, USA: Blackwell Publishing Ltd.; 2005. pp. 104-118.
25. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643-649. (Pubitemid 24215969)
26. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000; 96:2451-2459.
27. Weaver LK, Hintz-Goldstein KA, Pioli PA, Wardwell K, Qureshi N, Vogel SN, et al. Pivotal advance: Activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 2006; 80:26-35. (Pubitemid 44835523)
28. Weaver LK, Pioli PA, Wardwell K, Vogel SN, Guyre PM. Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol 2007; 81:663-671. (Pubitemid 46393544)
29. Connes P, Hue O, Tripette J, Hardy-Dessources MD. Blood rheology abnormalities and vascular cell adhesion mechanisms in sickle cell trait carriers during exercise. Clin Hemorheol Microcirc 2008; 39:179-184. (Pubitemid 352039993)
30. Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, et al. Coagulation changes in individuals with sickle cell trait. Am J Hematol 2002; 69:89-94. (Pubitemid 34111159)
31. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317-1322.
32. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289:1645-1651. (Pubitemid 37430269)
33. Rosse WF, Narla M, Petz LD, Steinberg MH. New views of sickle cell disease pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2000; 2000:2-17.
34. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254-2265.
35. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886-895. (Pubitemid 38252536)
36. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008; 93:20-26. (Pubitemid 351156147)
37. Onyekwere OC, Campbell A, Teshome M, Onyeagoro S, Sylvan C, Akintilo A, et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol 2008; 29:309-312. (Pubitemid 351414842)
38. Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 2006; 81:503-510.
39. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005; 19:771-784. (Pubitemid 41427109)
40. Roseff SD. Sickle cell disease: a review. Immunohematology 2009; 25:67-74.
41. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Polonifi A, Moyssakis I, et al. Cardiovascular effects of splenomegaly and splenectomy in betathalassemia. Ann Hematol 2005; 84:353-357. (Pubitemid 40823347)
42. Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksiri P, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol 2003; 78:139-145. (Pubitemid 37021954)
43. Westerman M, Pizzey A, Hirschman J, Cerino M, Eze A, Ramoton P, et al. Plasma 'free' HB is related to red cell derived vesicle numbers in sickle cell anemia and thalassemia intermedia: Implications for nitric oxide (NO) scavenging and pulmonary hypertension. Blood 2004; 104:465a.
44. Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 2006; 116:808-816. (Pubitemid 43326890)
45. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330:733-737. (Pubitemid 24080218)